ST. PETERSBURG, FL: March 14, 2002. Nutraceutical Clinical Laboratories International, Inc. (OTCBB: NCCL) today announced the appointment of Mr. Gary L. Harrison as President and Vice Chairman of the Board of Directors. The appointment is effective immediately.
Gary Harrison previously served as President and Chief Operating Officer of Mrs. Smith's Bakeries, the frozen and specialty baking operations for Flowers Foods (NYSE:FLO). During his more than 40-year career at Flowers, Mr. Harrison played an instrumental role in the growth of the company as he took on increasingly more challenging management assignments. As President of Mrs. Smith's, one of Mr. Harrison's many accomplishments included managing and developing the move by Flowers Foods into the frozen bakery segment of the industry.
"We are delighted to have attracted Gary Harrison to the company. Gary brings experienced executive leadership to our management team," said Paul Simmons, NCLII's Founder and Chief Executive Officer. "This appointment is part of our successful executive recruitment program which is bringing high caliber managers and board members to the company to take NCLII to the next stage of its growth. Gary Harrison's appointment is also a sign that we see enormous opportunities for our NuPreservTM product in the food, beverage and related industries" added Mr. Simmons.
"This is an exciting time to be joining the NCLII team," said Gary Harrison. "I look forward to forging a strong management team to rapidly expand the business as our products become more widely known in the marketplace. We will be incorporating professional management practices and aggressive sales and marketing methods into this burgeoning business," added Mr. Harrison. Mr. Harrison and his wife are natives of Florida.
About NCLII NCLII is committed to researching, designing, producing, and marketing their line of natural preservatives and anti-aging supplements using the highest quality standards, procedures, protocols, and controls. Our products will be manufactured according to the Food and Drug Administration (FDA) criteria for Good Manufacturing Practices (GMP) and are backed by scientific testing and clinical trials.
Nutraceutical Clinical Laboratories International, Inc. trades on the OTC market under the symbol “NCCL” and can be found on the Internet at: nasdaq.com, cnbc.com, pinksheets.com, and otcquote.com. Additional Company Information may be found at Nutraceutical Clinical Laboratories International, Inc.’s web site: www.nutradata.com.
Cautionary Statement: for Purposes of the ``Safe Harbor'' Provisions of the Private Securities Litigation Reform Act of 1995: All statements, other than historical facts, included in the foregoing news release regarding the Company's business strategy and plans of management for future operations are ``forward looking statements'' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements, which include, but are not limited to, words such as ``expect,'' ``anticipate,'' ``plan,'' ``estimate,'' ``project'' and ``intend'' are based on management's beliefs and assumptions, and on information currently available to management. Forward- looking statements involve certain known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These factors include, among others, the Company's ability to successfully implement its business plan; any uncertainties relating to business and economic conditions in markets in which the Company operates; any uncertainties relating to customer plans and commitments; the timely development and market acceptance of the Company's products and technologies; possible product defects and product liability, dependence on intellectual property rights, the highly competitive environment in which the Company operates and other risks detailed from time to time in the Company's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.
For further information, contact Investor Relations at InaVest, Inc., (toll free 866.774.6468).